Donate Help Contact The AHA Sign In Home
American Heart Association
Circulation
Search: search_blue_button Advanced Search
Circulation. 2006;114:e65
doi: 10.1161/CIRCULATIONAHA.106.613299
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Powers, H. J.
Right arrow Articles by Moat, S. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Powers, H. J.
Right arrow Articles by Moat, S. J.
Right arrowPubmed/NCBI databases
*Compound via MeSH
*Substance via MeSH
*Genetics Home Reference
Hazardous Substances DB
*RIBOFLAVIN
Related Collections
Right arrow Other Research
Right arrow Risk Factors

(Circulation. 2006;114:e65.)
© 2006 American Heart Association, Inc.


Correspondence

Letter by Powers et al Regarding Article, "Riboflavin Lowers Homocysteine in Individuals Homozygous for the MTHFR 677C->T Polymorphism"

Hilary J. Powers, BSc, PhD

Human Nutrition Unit, University of Sheffield, Sheffield, UK, h.j.powers{at}sheffield.ac.uk

Ian F.W. McDowell, MD, FRCP, FRCPath; Stuart J. Moat, BSc, PhD

Department of Medical Biochemistry and Immunology, University Hospital of Wales, Cardiff, UK

To the Editor:

We read with interest the paper by McNulty et al,1 in which it was shown that riboflavin supplements have a plasma homocysteine-lowering effect in people with marginal riboflavin status and moderately high plasma homocysteine (tHcy), apparently driven entirely by those people homozygous for the MTHFR C677T thermolabile variant. This finding makes an important contribution to the accumulating evidence of this gene–nutrient interaction.

Although it is reasonable to include riboflavin in considerations of the possible merits of food fortification with folate, it should be appreciated that the reported effect of riboflavin supplementation is confined to a selected group (people homozygous for the TT variant). Plasma tHcy levels in this group were almost twice those in a representative sample of men and women in the United Kingdom,2 in whom only the top 2.5% of women had values greater than 19µmol/L, in comparison with a mean value of 17.6µmol/L in the cohort presented by McNulty et al.

The sample of this study was not representative of the distribution of plasma tHcy and therefore cardiovascular risk in the United Kingdom and European populations.3 This compromises statistical inference and, in our opinion, the study should not be used as a basis for suggesting food policy.


*    Acknowledgments
 
Sources of Funding

Drs McDowell, Moat, and Powers received a research grant from the Food Standards Agency to study folate, riboflavin, and homocysteine lowering. Dr Powers has received funding from the Food Standards Agency to study riboflavin/genotype interactions.

Disclosures

None.


*    References
up arrowTop
*References
 

  1. McNulty H, Dowey, LC, Strain JJ, Dunne A, Ward M, Molloy AM, MccAnena LB, Hughes JP, Hannon-Fletcher M, Scott JM. Riboflavin lowers homocysteine in individuals homozygous for the MTHFR 677C->T polymorphism. Circulation. 2006; 113: 74–80.[Abstract/Free Full Text]
  2. Ruston D, Hoare J, Henderson L, Gregory J, Bates CJ, Prentice A, Birch M, Swan G, Farron M. The National Diet and Nutrition Survey: Adults Aged 19 to 64 Years. Volume 4: Nutritional Status. London, UK: HMSO; 2004.
  3. Graham IM, Daly LE, Refsum HM, Robinson K, Brattstrom LE, Ueland PM, Palma-Reis RJ, Boers GH, Sheahan RG, Israelsson B, Uiterwaal CS, Meleady R, McMaster D, Verhoef P, Witteman J, Rubba P, Bellet H, Wautrecht JC, de Valk HW, Sales Luis AC, Parrot-Rouland FM, Tan KS, Higgins I, Garcon D, Andria G. Plasma homocysteine as a risk factor for cardiovascular disease. The European Concerted Action project. JAMA. 1997; 277: 1775–1781.[Abstract]




This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Powers, H. J.
Right arrow Articles by Moat, S. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Powers, H. J.
Right arrow Articles by Moat, S. J.
Right arrowPubmed/NCBI databases
*Compound via MeSH
*Substance via MeSH
*Genetics Home Reference
Hazardous Substances DB
*RIBOFLAVIN
Related Collections
Right arrow Other Research
Right arrow Risk Factors